Hutchmed has finished rolling-in its NDA for the treatment of refractory metastatic colorectal cancer to the US FDA.

Hutchmed has finished rolling-in its NDA for the treatment of refractory metastatic colorectal cancer to the US FDA.

Hutchmed (China) Limited reports that it has finished the rolling submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for fruquintinib, a highly potent and selective oral inhibitor of VEGFR-1, -2, and -3, for…